Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) EBIT Margin (2022 - 2025)

BioXcel Therapeutics has reported EBIT Margin over the past 4 years, most recently at 4016.41% for Q4 2025.

  • Quarterly results put EBIT Margin at 4016.41% for Q4 2025, down 114947.0% from a year ago — trailing twelve months through Dec 2025 was 7859.97% (down 489240.0% YoY), and the annual figure for FY2025 was 7859.97%, down 489240.0%.
  • EBIT Margin for Q4 2025 was 4016.41% at BioXcel Therapeutics, up from 14518.37% in the prior quarter.
  • Over the last five years, EBIT Margin for BTAI hit a ceiling of 449714.29% in Q1 2022 and a floor of 28459.85% in Q3 2022.
  • Median EBIT Margin over the past 4 years was 6578.79% (2024), compared with a mean of 18253.66%.
  • Biggest five-year swings in EBIT Margin: crashed -47456768bps in 2023 and later skyrocketed 2070168bps in 2024.
  • BioXcel Therapeutics' EBIT Margin stood at 22224.37% in 2022, then skyrocketed by 76bps to 5285.9% in 2023, then surged by 46bps to 2866.94% in 2024, then tumbled by -40bps to 4016.41% in 2025.
  • The last three reported values for EBIT Margin were 4016.41% (Q4 2025), 14518.37% (Q3 2025), and 13210.0% (Q2 2025) per Business Quant data.